Bio Path reported $-488K in Operating Profit for its fiscal quarter ending in September of 2025.





Operating Profit Change Date
Alterity Therapeutics Limited AUD -8.07M 302.4K Dec/2025
Baxter International USD -214.2M 415.4M Dec/2025
Bio Path USD -488K 4.07M Sep/2025
Cipla INR 9.77B 6.21B Dec/2025
Clal Biotechnology ILS -1.74M 7.46M Dec/2022
Compugen USD 56.04M 63.93M Dec/2025
CSL USD 2.64B 1.97B Dec/2025
Grifols EUR 320.55M 91.01M Dec/2025
Karyopharm Therapeutics USD -17.84M 13.44M Dec/2025